人胎肝细胞生长因子治疗肝硬化52例临床研究  

A clinical study on treatment of liver cirrhosis by human embryo hepatocyte growth factor in 52 cases.

作　　者：邵福灵[1] 任锡玲[1] 李素琴[2] 符云峰[2] 

机构地区：[1]河北医科大学第二附属医院消化内科 [2]河北省医学科学院生化研究室

出　　处：《新医学》1999年第5期267-268,共2页Journal of New Medicine

基　　金：河北省科委科研课题

摘　　要：目的：探讨人胎肝细胞生长因子对肝硬化的治疗作用。方法：用人胎肝细胞生长因子肌肉注射治疗肝硬化５２例（治疗组），每日６ｍｇ，１０天为１疗程。对照组３４例，给予常规治疗。结果：经过１个疗程治疗后，治疗组的ＡＬＴ、胆红素比治疗前显著降低（Ｐ＜０．０５），清蛋白、凝血酶原活动度等指标比治疗前明显升高（Ｐ＜０．０５）；免疫指标仅ＩｇＧ、Ｃ３比治疗前有明显改变（Ｐ＜０．０５），但在治疗两个疗程后，各免疫指标（ＩｇＧ、ＩｇＡ、ＩｇＭ、Ｃ３）均有显著性改变（Ｐ＜０．０５），对照组治疗前后无明显改变。结论：提示加大人胎肝细胞因子的剂量或延长疗程会使肝硬化病情得到进一步改善。Objective: To investigate the therapeutic effects of human embryo hepatocyte growth factor on liver cirrhosis. Methods: Human embryo hepatocyte growth factor was administrated intramuscularly in dosage of 6 mg per day for 10 days to 52 patients with liver cirrhosis. Other 34 control cases were given regular therapy. Results: At the end of first therapeutic course with human embryo hepatocyte growth factor, significant reduction in ALT and SB, increase in albumin and PTA ( P <0 05), and significant improvement in partial immune indices indicating that IgG and C3 ( P <0 05) were found. At the end of second therapeutic course, all the immune indices (IgG, IgA, IgM, C3) had significant improvement ( P <0.05). Conclusion: Increasing the dosage and prolonging the therapeutic course of the hepatocyte growth factor can further improve the therapeutic effects on liver cirrhosis.

关 键 词：肝细胞生长因子 肝硬化 治疗 HGF 

分 类 号：R575.205[医药卫生—消化系统] R977.6[医药卫生—内科学]